Your browser doesn't support javascript.
loading
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Kulke, M H; Ruszniewski, P; Van Cutsem, E; Lombard-Bohas, C; Valle, J W; De Herder, W W; Pavel, M; Degtyarev, E; Brase, J C; Bubuteishvili-Pacaud, L; Voi, M; Salazar, R; Borbath, I; Fazio, N; Smith, D; Capdevila, J; Riechelmann, R P; Yao, J C.
Affiliation
  • Kulke MH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Ruszniewski P; Department of Gastroenterology and Pancreatology University of Paris VII and Beaujon Hospital, Paris, France.
  • Van Cutsem E; Department of Digestive Oncology, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium.
  • Lombard-Bohas C; Department of Medical Oncology, Edouard Herriot Hospital, Lyon, France.
  • Valle JW; Department of Medical Oncology, University of Manchester/The Christie Hospital, Manchester, UK.
  • De Herder WW; Department of Endocrine Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Pavel M; Department of Hepatology and Gastroenterology, Charité University of Medicine, Berlin, Germany.
  • Degtyarev E; Department of Oncology, Novartis AG, Basel, Switzerland.
  • Brase JC; Department of Oncology, Novartis AG, Basel, Switzerland.
  • Bubuteishvili-Pacaud L; Department of Oncology, Novartis AG, Basel, Switzerland.
  • Voi M; Department of Oncology, Novartis Pharmaceuticals Corporation, East Hanover, USA.
  • Salazar R; Department of Medical Oncology, Catalan Institute of Oncology, IDIBELL, Hospital of Barcelona, Barcelona, Spain.
  • Borbath I; Department of Gastroenterology Saint-Luc University Hospital, Brussels, Belgium.
  • Fazio N; Department of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy.
  • Smith D; Department of Oncology, St. Andrew Hospital, Bordeaux, France.
  • Capdevila J; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Riechelmann RP; Department of Oncology, Cancer Institute of the State of São Paulo, São Paulo, Brazil.
  • Yao JC; Department of Gastrointestinal and Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
Ann Oncol ; 28(6): 1309-1315, 2017 06 01.
Article in En | MEDLINE | ID: mdl-28327907
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Neuroendocrine Tumors / Everolimus Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Neuroendocrine Tumors / Everolimus Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Affiliation country: Country of publication: